Business Context and Reporting Period
This Form 8-K is filed by Conduit Pharmaceuticals Inc. (CDT) on March 5, 2025. The company is an emerging growth company incorporated in Delaware with principal executive offices in Naples, FL. The filing addresses the company's compliance status with The Nasdaq Stock Market LLC listing rules.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. However, it references the following financial thresholds required for listing compliance:
- Market Value of Publicly Held Shares (MVPHS): Targeting compliance with the Nasdaq Capital Market standard of greater than $1.0 million.
- Stockholder's Equity: Targeting compliance with the Equity Standard of greater than $2.5 million.
- Minimum Bid Price: Compliance was regained as of February 26, 2025.
Material Changes and Events
On March 5, 2025, the Nasdaq Hearing Panel granted Conduit Pharmaceuticals an extension to regain compliance with specific listing rules. Key developments include:
- Extension Granted: The Panel extended the deadline for compliance with Market Value of Publicly Held Shares (MVPHS) and Market Value of Listed Securities (MVLS) rules.
- Bid Price Compliance: The company confirmed it regained compliance with the Minimum Bid Price rule as of February 26, 2025.
- Market Transfer: The company intends to file an application to transfer from the Nasdaq Global Market to the Nasdaq Capital Market by March 12, 2025.
Guidance, Outlook, and Risks
Management intends to demonstrate full compliance with all Nasdaq listing rules by March 31, 2025. The company believes it will satisfy the MVPHS and Stockholder's Equity standards upon transfer to the Nasdaq Capital Market. However, the filing explicitly states that no assurance can be given that these standards will be met to Nasdaq's satisfaction.
Investor Verification Checklist
- Verify the filing of the application to transfer to the Nasdaq Capital Market by March 12, 2025.
- Confirm the company's demonstration of compliance with MVPHS and MVLS rules by the March 31, 2025 deadline.
- Monitor the company's Stockholder's Equity to ensure it remains above the $2.5 million threshold.
- Review subsequent filings for any updates on the Minimum Bid Price stability.